Asciminib (Asciminib) is an allosteric inhibitor targeting the myristyl pocket of ABL1. It has been approved by the U.S. Food and Drug Administration (FDA)Approved for use in patients with chronic phase (CP) chronic myeloid leukemia (CML) resistant or intolerant to ≥ 2 patients with previous TKI or T315I mutations. Due to the development of effectiveBCR::ABL1 tyrosine kinase inhibitors (TKIs), the prognosis of CP-CML patients has improved significantly. However, approximately 15-20% of patients ultimately experience treatment failure due to resistance or intolerance to TKI therapy. In a phase 1 trial, aceminib monotherapy showed a relatively favorable safety profile and effective efficacy in patients with and without the T315I mutation.
.jpeg)
